Ambit gets new CEO; Tibotec files NDA for HIV therapy; Daiichi Sankyo forms vax venture;

 @FierceBiotech: GlobeImmune cuts 25% of staff. Report | Follow @FierceBiotech

> The executive chairman of Ambit, Alan Lewis has been named CEO of the kinase drug developer. Lewis had been president and CEO of the Juvenile Diabetes Research Foundation, which has been an ambitious backer of new diabetes therapies. Ambit release

> Tibotec has submitted its NDA for the HIV therapy TMC278 (rilpivirine). Release

> The FDA has approved Daiichi Sankyo's Tribenzor, a three-in-one therapy that combines olmesartan medoxomil, amlodipine and hydrochlorothiazide for hypertension. Release

> Daiichi Sankyo and the Kitasato Institute Research Center for Biologicals have formed a joint venture to develop new flu vaccines. Story

> Berkeley, CA-based Xoma announced this morning that it has nabbed a $750,000 milestone from its collaboration with Aveo. Xoma release

> An experimental treatment for sickle cell disease developed at LA BioMed has entered Phase III clinical trials. Release

And Finally... Veteran biotech investors know just how hard it is to bet on a possible M&A deal, as the ongoing Genzyme story illustrates. When one stock goes up on a rumor, notes the Wall Street Journal, another possible target can see its shares dive when the spotlight shifts. Report

Suggested Articles

CureVac will spend the bulk of the proceeds on its COVID-19 vaccine, with the rest going to manufacturing, platform development and other programs.

WuXi names Dong to helm new vaccines CDMO; Paragon appoints Jimenez as capital makers lead; Levy joins Spark as CMO.

The phase 1 and 2 results suggest the vaccine may be safe, tolerable and capable of triggering production of antibodies against the coronavirus.